

# The Pennsylvania Heroin Overdose Prevention Technical Assistance Center

Janice Pringle, PhD  
Director, Program Evaluation  
and Research Unit  
University of Pittsburgh  
School of Pharmacy




**Collaborating with the community  
is the cornerstone for efforts to  
improve public health.<sup>1</sup>**



# Community efforts to reduce overdoses are emerging throughout the US.<sup>2</sup>




# What Works:<sup>2</sup>




**Prescription Drug  
Monitoring Programs**



**Medication Assisted  
Treatment**



**Naloxone Availability**



**Opioid Prescription  
Practices**

**Some community efforts have  
been successful.<sup>3,4</sup>**




# What would a Community Coalition That Addresses Overdose Look Like?



# The coalition may be comprised of:

Persons who represent:  
the population at risk, the  
services the population  
needs, the policy entities  
that can change practices  
and the community's  
values.




**The coalition members work together to effectively ensure that their communities are safer, healthier, and drug free.**




# Making Your Community Coalition Successful: Preparation is KEY



# Framework




# Clearly define your VISION/GREATER PURPOSE




# Understand your community's **CURRENT CONDITION**


- **Culture**
- **Economy**
- **Social Networks**
- **Power Structures**
- **Norms and Values**
- **History**
- **Current or Previous  
Overdose Experience**



# Identify the best LEADERSHIP for your coalition.




**Identify the best coalition MEMBERS  
needed to achieve your Vision based on  
your community's Current Condition.**



# Examples of COALITION MEMBERS

- **Representatives from Criminal Justice**
- **Police**
- **Healthcare Providers**
- **Single County Authorities**
- **Community Organizations**
- **Family Members**
- **Recovery Organizations**
- **Others**



# COALITION MEMBERS can change based on:

- **Participation**
- **Funding**
- **Healthcare Providers**



# Role of the TECHNICAL ASSISTANCE CENTER – Assist Your Community to:

- **Develop Vision**
- **Identify Leaders**
- **Develop Coalition**
- **Help Review Data**
- **Develop a Strategic Plan**
- **Identify Evidence-Based Practices**
- **Develop an Evaluation Plan**
- **Obtain Additional Resources**
- **Maintain a Healthy Coalition Culture**



Additionally, the Technical Assistance Center will further develop OverdoseFreePA.org to provide more shared and individualized resources.

**OverdoseFreePA**

Pennsylvania's town square for overdose prevention information

Search

Home News Overdose Data Education Local Resources About **Emergency?**

## Resources for School and Work Leaders

Answering your questions about:

- Addressing substance abuse at school or work
- Support and treatment options
- Peer Assistance

There is an overdose epidemic. [Be informed.](#)

Thousands of drug users are rescuing one another with antidote naloxone

Why Is It So Difficult to Get Drug Treatment?

2013 Heroin Diversion Monitor Report

Effort to Curb Painkiller Abuse Falls Short at Pharmacy

Reducing Substance Misuse: What Really Works?

# REFERENCES

1. Agency for Toxic Substance and Disease Registry. *Principles of Community Engagement*. Second Edition. June 2011. NIH.  
[http://www.atsdr.cdc.gov/communityengagement/pdf/PCE\\_Report\\_508\\_FINAL.pdf](http://www.atsdr.cdc.gov/communityengagement/pdf/PCE_Report_508_FINAL.pdf)
2. U.S. Department of Health and Human Services. *Opioid Abuse in the US and HHS Actions to Address Opioid-Drug R Overdoses and Deaths*. <https://aspe.hhs.gov/basic-report/opioid-abuse-us-and-hhs-actions-address-opioid-drug-related-overdoses-and-deaths>
3. Substance Abuse and Mental Health Services Administration. *Massachusetts Prevention Efforts Target Opioid Overdoses*. September 2015. <http://www.samhsa.gov/capt/tools-learning-resources/massachusetts-prevention-targets-opioid-overdose>
4. Project Lazarus. *Community-based Overdose Prevention and Opioid Safety with Community Care of North Carolina*

# Thank You!

**Janice Pringle, PhD**

Director, Program Evaluation and Research Unit  
University of Pittsburgh School of Pharmacy

Phone: 412-383-2005

Email: [jlpringle@pitt.edu](mailto:jlpringle@pitt.edu)

# Gathering Your Community Overdose Death Data

Dr. Karl Williams



# **Misconception #1**

We know why people are dying today.



➤ About the fastest turnaround time for toxicology is a week

## Reality

➤ We know why people died yesterday, Complex cases can take months.

## last month or last year

➤ Resolution of overdose cases often require knowledge of what was present at the scene of the death.

# A Question on Opioid Overdoses...

does the presence of morphine alone mean heroin contributed to death?

✍ **YES**, if morphine is present in the blood.



✍ **YES**, if morphine is present in urine **with** 6-MAM present in blood.



✍ **NO**, if morphine is **only** present in urine.



# Case #1

## Straight Forward



# Case #1

## What We Know About the Death

- ✍ 43 year old white male with known history of “**drug abuse**”
- ✍ Known to use **heroin** daily
- ✍ Found “down at home” by 21 year old daughter
- ✍ Daughter directs police to **syringe** in garbage
- ✍ Daughter states that **stamp bag** for “**Oxyclean**” was seen
- ✍ Down time: 1-30 minutes
- ✍ EMS transports patient to hospital; **resuscitation fails**

# Case #1

## What We Learn From the Toxicology Report

Positive for Fentanyl  
**Femoral Blood**  
6.8 ng/ml

Positive for Fentanyl  
**Urine**  
Positive for Morphine

KARL E. WILLIAMS, M.D., M.P.H., MEDICAL EXAMINER  
ALLEGHENY COUNTY OFFICE OF THE MEDICAL EXAMINER  
FORENSIC LABORATORY DIVISION  
1520 Penn Avenue, Pittsburgh, PA 15222

Laboratory Case 15LAB02965 Report# 1 Pathology Case No: 15COR02803 Date June 01, 2015

Deceased Name: Ray G. Smith

Autopsy Prosecutor: Karl E. Williams Autopsy Technician: B. Harmon Date of Autopsy: 04/04/2015

7 - Femoral Blood

GC/MS

Morphine	Not Detected
6-monoacetylmorphine	Not Detected
Codeine	Not Detected
Oxycodone	Not Detected
Oxymorphone	Not Detected
Hydrocodone	Not Detected
Hydromorphone	Not Detected
Fentanyl	6.8 ng/mL

8 - Urine

GC Headspace

Alcohol	Not Detected
---------	--------------

ELISA

Benzodiazepines	Not Detected
Cocaine metabolite	Not Detected
Opiates	Positive
Oxycodone	Not Detected
Fentanyl	Positive

GC/MS

Fentanyl	Positive
Morphine	Positive
6-monoacetylmorphine	Not Detected
Codeine	Not Detected
Oxycodone	Not Detected
Oxymorphone	Not Detected
Hydrocodone	Not Detected
Hydromorphone	Not Detected

\* Result indicates that further testing is required. Refer to quantitation above for final result.

# Case #1

Daily "heroin" use

Day before death dealer provided him with his usual heroin

Day of death dealer supplied **different** stamp bag

**Morphine** in urine most likely represents end of metabolism from day before

**Fentanyl** in blood is the drug that resulted in death

# Case #2

## Complex

# Case #2

## Cannabinoids a contributor?

Not now if it represents smoked marijuana, but possible in the future with synthetics.

Westmoreland County Coroner's Office  
Attn: Kenneth A. Bacha  
2503 S. Grande Blvd  
Greensburg, PA 15601

Page 1 of 7

### Positive Findings:

<u>Compound</u>	<u>Result</u>	<u>Units</u>	<u>Matrix Source</u>
Ethanol	315	mg/dL	001 - Blood
Blood Alcohol Concentration (BAC)	0.315	g/100 mL	001 - Blood
Cotinine	Positive	ng/mL	001 - Blood
Alprazolam	20	ng/mL	001 - Blood
Delta-9 THC	4.2	ng/mL	001 - Blood
Delta-9 Carboxy THC	13	ng/mL	001 - Blood
Clozapine	610	ng/mL	001 - Blood
Norclozapine	860	ng/mL	001 - Blood
Tramadol	500	ng/mL	001 - Blood
O-Desmethyltramadol	160	ng/mL	001 - Blood
Trazodone	0.15	mcg/mL	001 - Blood
Benzodiazepines	Presump Pos	ng/mL	003 - Urine
Cannabinoids	Presump Pos	ng/mL	003 - Urine

See Detailed Findings section for additional information

### Testing Requested:

<u>Analysis Code</u>	<u>Description</u>
8050U	Postmortem Toxicology - Urine Screen Add-on (6-MAM Quantification only)
8052B	Postmortem Toxicology - Expanded, Blood (Forensic)

### Tests Not Performed:

Part or all of the requested testing was unable to be performed. Refer to the Analysis Summary and Reporting Limits section for details.

### Specimens Received:

<u>ID</u>	<u>Tube/Container</u>	<u>Volume/ Mass</u>	<u>Collection Date/Time</u>	<u>Matrix Source</u>	<u>Miscellaneous Information</u>
001	Gray Top Tube	9.5 mL	10/11/2014 13:00	Blood	
002	Gray Top Tube	9.25 mL	10/11/2014 13:00	Blood	
003	Red Top Tube	9 mL	10/11/2014 13:00	Urine	
004	Red Top Tube	8.75 mL	10/11/2014 13:00	Bile	

# Case #2

## Positive Findings:

Compound	Result	Units	Matrix Source
Lorazepam	71	ng/mL	001 - Peripheral Blood
Clonazepam	4.1	ng/mL	001 - Peripheral Blood
7-Amino Clonazepam	76	ng/mL	001 - Peripheral Blood
Oxycodone - Free	600	ng/mL	001 - Peripheral Blood
Oxymorphone - Free	1.5	ng/mL	001 - Peripheral Blood
Quetiapine	190	ng/mL	001 - Peripheral Blood
Fluoxetine	270	ng/mL	001 - Peripheral Blood
Norfluoxetine	530	ng/mL	001 - Peripheral Blood
Trazodone	0.10	mcg/mL	001 - Peripheral Blood
Opiates	Presump Pos	ng/mL	003 - Urine
Benzodiazepines	Presump Pos	ng/mL	003 - Urine
Oxycodone	Presump Pos	ng/mL	003 - Urine

See Detailed Findings section for additional information

## Testing Requested:

Analysis Code	Description
8050U	Postmortem Toxicology - Urine Screen Add-on (6-MAM Quantification only)
8052B	Postmortem Toxicology - Expanded, Blood (Forensic)


## Tests Not Performed:

Part or all of the requested testing was unable to be performed. Refer to the Analysis Summary and Reporting Limits section for details.

## Specimens Received:

ID	Tube/Container	Volume/Mass	Collection Date/Time	Matrix Source	Miscellaneous Information
001	Gray Top Tube	8 mL	11/17/2014 16:00	Peripheral Blood	
002	Gray Top Tube	7 mL	11/17/2014 16:00	Peripheral Blood	
003	Red Top Tube	9.75 mL	11/17/2014 16:00	Urine	
004	Red Top Tube	5 mL	11/17/2014 16:00	Bile	

v.13



## **Misconception #2**

We can rely on some high degree of uniform reporting between various agencies (Coroner/ME) dealing with drug overdose death.



# Reality

- ✍ There is enormous variation in training between coroners (especially elected) and medical examiners on drug effects, metabolism and redistribution. **There is no "Gold Standard" or even Standard Operating Procedure for analyzing and reporting drug overdoses.**
- ✍ There can even be significant variation between Medical Examiner offices.

# Reality

- ✍ Consider the **cannabinoids** – rapidly changing molecular configuration with increasing toxic side effects.
- ✍ Few were evaluated as primary overdose drug.
- ✍ New configurations of **stimulants** are discovered daily.

The arena of drug overdoses is evolving rapidly.

## **Misconception #3**

We can rely on some high degree of uniform reporting with overdose **survivors**.



# Reality

✍ Few hospital labs have the capabilities of forensic laboratories.

## Overdoses that survive wind up in

## Emergency Departments.

✍ Until recently, most hospitals would screen blood and urine and treat symptomatically.

✍ Full forensic toxicology is complex and expensive.

## **Misconception #4**

This is only a concern at the national level.



- Documenting overdoses needs to happen at the most granular level possible.

## Reality

The overdose crisis happens at a local

## level.

- Efforts to combat overdoses need to happen locally and depend on this up-to-date granular data.
- Recognizing the importance of the local level allows for optimal cooperation between law enforcement and community groups.

# Other Issues

- ✍ The advantage of having a Toxicology Laboratory and Drug Chemistry section under the same roof and part of the same Laboratory Information System – ACOME
- ✍ The independent Forensic Laboratory

# Developing a Strategic Plan to Address Overdoses Within Your Community

Janice Pringle, PhD  
Director, Program Evaluation  
and Research Unit  
University of Pittsburgh  
School of Pharmacy


# Steps to Developing your Strategic Plan



**FIRST: Define the outcome you want to impact as specifically as possible based on your data.**




**SECOND: Use your data or literature to describe the HOW, WHERE, WHAT and WHEN your target population uses opioids associated with overdose.**



**THIRD: Use your data or literature to determine the FACTORS that are associated with increasing or reducing the target population's opioid use or death.**



# FOURTH: Determine the Evidence-Based Practices that could theoretically reduce your targets opioid associated outcome.




Prescription Drug Monitoring Programs (PDMPs)



Medication Assisted Treatment



Naloxone Availability




Opioid Prescription Practices

# EXAMPLE




# OUTCOME

**Reduce overdoses and overdose deaths among people aged 18-24.**



# HOW, WHAT, WHERE, WHEN



- Opioid use starts in high school.
- Heroin users tend to use opioids first.
- Most overdoses involve heroin, opioids, alcohol and marijuana.
- Youth overdoses end in Emergency Departments.
- Probable previous experience with SUD or mental health treatment.
- Probable previous experience in juvenile justice system.
- Unstable living or housing situation; usually have children.

# INTERVENING FACTORS

- Prescribers not using PDMPs



- Low Naloxone Availability




- Youth not identified by systems (school, criminal justice, physicians, etc.)



- Little to no access to MAT, SUD treatment and recovery services




# EVIDENCE-BASED PRACTICES




**Prescription Drug  
Monitoring Programs  
(PDMPs)**



**Medication Assisted  
Treatment**



**Naloxone Availability**




**Opioid Prescription  
Practices**

# How do you choose your Evidence-Based Practices and Implementation Time Frames?

# Match selected EVIDENCE-BASED PRACTICES with TIME FRAMES that allow quick implementation and high effectiveness.

- This Year?



- Within Two Years?



- Longer?

# Determine how you will EVALUATE your plan once implemented.



**The Technical Assistance Center will help you develop your strategic and evaluation plans via an individualized concierge service.**



# OverdoseFreePA.org will contain a list of potential practices, relevant resources, strategic plans, and evaluation results reflecting the work of participating communities.

<a href="#">Home</a>	<a href="#">News</a>	<a href="#">Overdose Data</a>	<a href="#">Education</a>	<a href="#">Local Resources</a>	<a href="#">About</a>	<a href="#">Emergency?</a>
----------------------	----------------------	-------------------------------	---------------------------	---------------------------------	-----------------------	----------------------------

Allegheny	Clearfield	Greene	Perry
Berks	Cumberland	Jefferson	Washington
Blair	Clinton	Lehigh	Westmoreland
Bucks	Dauphin	Luzerne	Wyoming
Butler	Delaware	Lycoming	

Single County Authority (SCA)	Additional Resources
-------------------------------	----------------------

<p><b>Allegheny County</b></p> <p>Latika D. Davis-Jones, PhD, MPH, MSW  <a href="#">Allegheny County Department of Human Services</a>   Office of Behavioral Health   Bureau of Drug and Alcohol Services</p> 		<p><a href="#">The Allegheny County Overdose Prevention Coalition (ACOPC)</a></p> <p><a href="#">Prevention Point Pittsburgh (Needle Exchange and Overdose Prevention Training)</a></p> <p><a href="#">The Allegheny County Health Department's Overdose Resources Page</a></p>
---	---	---

# Thank You!

**Janice Pringle, PhD**

Director, Program Evaluation and Research Unit  
University of Pittsburgh School of Pharmacy

Phone: 412-383-2005

Email: [jlpringle@pitt.edu](mailto:jlpringle@pitt.edu)